Efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet in mono- and polysensitized subjects

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 68, Issue 2, 2013, Pages 252-255

  Nelson, H ^a   Blaiss, M ^b   Nolte, H ^c   Wurtz S O ^d   Andersen, J S ^d   Durham, S R ^e  

^a DEPARTMENT OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d ALK ABELLÓ   (Denmark)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

grass allergy; Phleum pratense; polysensitization; rhinoconjunctivitis; sublingual immunotherapy

Indexed keywords

GRASS POLLEN VACCINE; PLACEBO;

APPLICATION SITE REACTION; ARTICLE; ASTHMA; DESENSITIZATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EAR PRURITUS; HUMAN; IMMUNOTHERAPY; MOUTH EDEMA; ORAL PRURITUS; PHLEUM PRATENSE; POST HOC ANALYSIS; PRICK TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOCONJUNCTIVITIS; SYMPTOMATOLOGY; THROAT IRRITATION;

ADMINISTRATION, SUBLINGUAL; ADULT; ANTIGENS, PLANT; CHILD; CHILD, PRESCHOOL; DESENSITIZATION, IMMUNOLOGIC; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PATIENT SAFETY; PHYTOTHERAPY; PLANT EXTRACTS; POACEAE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHINITIS, ALLERGIC, SEASONAL; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TABLETS; TREATMENT OUTCOME;

EID: 84872424989     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12074     Document Type: Article

References (15)

1. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S,. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117: 802-809.
2. Dahl R, Stender A, Rak S,. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006; 61: 185-190.
3. Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablet for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 118: 434-440.
4. Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W, et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2008; 121: 512-518.
5. Durham SR, Emminger W, Kapp A, Colombo G, de Monchy JG, Rak S, et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010; 125: 131-138.
6. Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009; 123: 167-173.
7. Nelson HS, Nolte H, Creticos P, Maloney J, Wu J, Bernstein DI,. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol 2011; 127: 72-80.
8. Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner DP,. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 2011; 127: 64-71.
9. Kim KW, Kim EA, Kwon BC, Kim ES, Song TW, Sohn MH, et al. Comparison of allergic indices in monosensitized and polysensitized patients with childhood asthma. J Korean Med Sci 2006; 21: 1012-1016.
10. Ciprandi G, Incorvaia C, Puccinelli P, Soffia S, Scurati S, Frati F,. Polysensitization as a challenge for the allergist: the suggestions provided by the Polysensitization Impact on Allergen Immunotherapy studies. Expert Opin Biol Ther 2011; 11: 715-722.
11. Lee JE, Choi YS, Kim MS, Han DH, Rhee CS, Lee CH, et al. Efficacy of sublingual immunotherapy with house dust mite extract in polyallergen sensitized patients with allergic rhinitis. Ann Allergy Asthma Immunol 2011; 107: 79-84.
12. Malling HJ, Montagut A, Melac M, Patriarca G, Panzner P, Seberova E, et al. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis. Clin Exp Allergy 2009; 39: 387-393.
13. Didier A, Malling H, Worm M, Horak F, Jäger S, Montagut A, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 120: 1338-1345.
14. Amar SM, Harbeck RJ, Sills M, Silveira LJ, O'Brien H, Nelson HS,. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract. J Allergy Clin Immunol 2009; 124: 150-156.
15. Calderon MA, Cox L, Casale TB, Moingeon P, Demoly P,. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. J Allergy Clin Immunol 2012; 129: 929-934.